Ximedica Joins Theorem Clinical Research Strategic Alliance Group
News Sep 12, 2013
Theorem Clinical Research has announced the addition of Ximedica, a medical product development firm, to its roster of strategic alliances.
With deep expertise in human factors engineering, industrial design, mechanical, electrical and software engineering, advanced manufacturing services and regulatory requirements, Ximedica brings more than 25 years of experience developing medical devices, combination products and consumer health care products to the alliance.
Ximedica’s product development experience includes programs involving complex electro-mechanical systems, fluid management systems, graphical user interfaces, portable or wearable systems and systems with cutting-edge wireless technology and miniaturization solutions.
“Theorem works with Ximedica to create design solutions that meet the safety and use requirements of a wide range of populations, thereby minimizing risk during the regulatory review process,” said D. Lee Spurgin Jr., Ph.D., Theorem senior vice president and general manager of medical device and diagnostic development.
Spurgin continued, “We feel these types of business alliances allow us to offer a better end product to clients.”
“Recognizing that a growing number of our product development programs are requiring large-scale, multi-center global clinical studies, it made sense for Ximedica to partner with a reputable, global CRO such as Theorem. Our combined expertise provides a more compelling solution for our global clients,” said Ximedica CEO Randall S. Barko.
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Cancer Cells Force Normal Cells to Act Like Viruses, Helping Tumors SpreadNews
Researchers reveal how cancer cells force normal cells to act like viruses – allowing tumors to grow, resist treatment, and spread.READ MORE
Edith Heard Unanimously Selected as Next Director General of EMBLNews
At its 53rd meeting yesterday, EMBL Council selected Edith Heard as the organization’s fifth Director General. Heard’s mandate is scheduled to begin 1 January 2019.READ MORE
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Target Engagement in Biology and Drug Discovery
Feb 19 - Feb 23, 2018